Gleicher, Norbert
Kushnir, Vitaly A.
Darmon, Sarah K.
Wang, Qi
Zhang, Lin
Albertini, David F.
Barad, David H.
Funding for this research was provided by:
Foundation for Reproductive Medicine (n/a)
Center for Human Reproduction (n/a)
Article History
Received: 14 September 2017
Accepted: 11 December 2017
First Online: 6 January 2018
Compliance with ethical standards
:
: N.G, and D.H.B, are co-inventors on a number of pending and already awarded U.S. patents claiming therapeutic benefits from androgen supplementation in women with low functional ovarian reserve (LFOR) and relating to the FMR1 gene in a diagnostic function in female fertility. Both receive royalties from Fertility Nutraceuticals, LLC, in which N.G. also holds shares. N.G., D.H.B and V.A.K. also are co-inventors on three pending AMH-related patent applications. All authors received research grants, travel funds and speaker honoraria from Pharma companies, though none in any way related to hear presented materials. The remaining authors declare that they have no conflict of interest.